MANCHESTER, England – (COMMERCIAL THREAD) – Hologic, Inc. (Nasdaq: HOLX) today announced its large European launch of Novodiag® system, a fully automated molecular diagnostic solution for on-demand infectious disease and antimicrobial resistance testing. The launch follows Hologic’s acquisition of Mobidiag Oy in June 2021 and will bring the benefits of the Novodiag system to a wider range of customers in Europe.
The Novodiag system combines real-time PCR and DNA microarray capabilities. This enables the identification of multiple pathogens in a single sample, providing a quick and easy way to identify patients at highest risk through targeted and syndromic testing on demand. Its CE-IVD test menu includes highly multiplexed on-demand tests for gastrointestinal infections and antibiotic resistance, as well as a targeted test for the detection of SARS-CoV-2. A strong pipeline is also under development.
“Our acquisition of Mobidiag was aimed at strengthening our international diagnostics business. With Hologic’s launch of the Novodiag system, we are achieving this goal, ”said Jan Verstreken, Group President, International at Hologic. “The addition of the Novodiag system to our scalable molecular diagnostic solutions portfolio will provide more customers in Europe with a wider choice of solutions that meet their needs, from rapid single patient testing to population-level screening. ”
Hologic’s current diagnostic offering is anchored by the Panther® System, a best-in-class, fully automated, results-based sample analysis platform designed for use in variable throughput laboratories. The Novodiag system is a high multiplexing technology that is precision engineered for simplicity, accuracy and affordability across a wide and growing menu of high and low plex tests. It complements the Panther system, as well as Panther’s scalable solutions, and expands Hologic’s offering, enabling the company to meet the growing diagnostic testing needs of customers, from the smallest to the largest laboratories.
Tuomas Tenkanen, CEO of Mobidiag, a Hologic company, said: “Mobidiag is already realizing the benefits of being part of the Hologic family, and today’s launch will allow Novodiag to reach a market of many customers faster. larger, offering the advantages of an on-demand service system that offers ease of use, high multiplexing capacity and fast turnaround time.
For more information, visit https://www.hologic.com/hologic-products/novodiag-system.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company focused primarily on improving the health and well-being of women through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, Mobidiag, Novodiag, Panther and associated logos are trademarks and / or registered trademarks of Hologic, Inc. and / or its subsidiaries in the United States and / or other countries.
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the launch of the Novodiag system and associated tests. There can be no assurance that these products will provide the benefits described in this document, that they will be commercially successful or that they will achieve the expected level of sales, or that these efforts will be successful, will benefit the Company and its shareholders. or will improve over time. Hologic expressly disclaims any obligation or commitment to publicly post any update or revision to any such statements presented herein to reflect any change in expectations or in the events, conditions or circumstances upon which such data or statements are based.
SOURCE: Hologic, Inc.